DOCSLIB.ORG

ABSTRACTS of the 20Th ANNUAL MEETING of the ITALIAN SOCIETY of URO-ONCOLOGY (Siuro)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ABSTRACTS of the 20Th ANNUAL MEETING of the ITALIAN SOCIETY of URO-ONCOLOGY (Siuro) ANTICANCER RESEARCH 30: 1375-1544 (2010) ABSTRACTS OF THE 20th ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO) Rome, June 23-25, 2010 Catholic University of the Sacred Heart Faculty of Medicine “A. Gemelli ” Centro Congressi Europa, Largo Francesco Vito, 1, Rome, Italy Chair: Gigliola Sica Honorary Chair: Pier Francesco Bassi Advisory Committee: Giorgio Arcangeli Cora Sternberg Giuseppe Vespasiani Organizing Secretariat Italian Society of Uro-Oncology (SIUrO) Emilia Viaggi Congressi & Meeting S.r.l. President: Giuseppe Martorana Via Porrettana, 76 40033 Casalecchio di Reno (BO) tel. + 39 051 6194911 – fax + 39 051 6194900 e-mail: [email protected] web: www.emiliaviaggi.it Scientific Secretariat Società Italiana di Urologia Oncologica (SIUrO) c/o Clinica Urologica, Alma Mater Studiorum Catholic University of the Sacred Heart Università di Bologna Permanent Training Office Policlinico S. Orsola Malpighi tel. + 39 06 30154886 – fax +39 06 3055397 Padiglione Palagi, via P. Palagi, 9 – 40138 Bologna e-mail: [email protected] tel. +39 051 6362421 – 051 302082 – fax +39 051 308037 web: www.rm.unicatt.it e-mail: [email protected] – web: www.siuro.it Abstracts of the 20th Annual Meeting of SIUrO, Rome, June 23-25, 2010 1 Objective: To evaluate the functional and oncological LAPAROSCOPIC VERSUS OPEN RADICAL outcomes of laparoscopic partial nephrectomy (LPN) in NEPHRO-URETERECTOMY FOR UPPER URINARY comparison with open partial nephrectomy (OPN) for renal TRACT UROTHELIAL CANCER: ONCOLOGICAL tumour. OUTCOMES AND 5-YEAR FOLLOW-UP Patients and Methods: Between July 1997 and January 2004, 125 LPN and 125 OPN were performed in our Clinic. Francesco Greco, Sigrid Wagner, Rashid M. Hoda, Amir Preoperatively, all the patients underwent intravenous Hamza and Paolo Fornara pyelography and computed tomography (CT) for detailed information on tumour size, location, extent of parenchymal Department of Urology and Kidney Transplantation, Martin infiltration, and proximity to the pelvicaliceal system. Luther University, Halle/Saale, Germany Demographic data (age, gender), perioperative and postoperative parameters, including operating time, estimated Laparoscopic surgery is increasingly accepted in the treatment blood loss, complications, length of hospital stay, renal of urological pathology. We compared the oncological function, histological tumour staging and grading, and outcomes of laparoscopic vs. open nephro-ureterectomy for metastasis rates were collected and analysed. upper urinary tract transitional cell carcinoma. Results: The mean operative time for LPN and OPN was Patients and Methods: Between July 1999 and January 135 min and 165 min, respectively. 2003, 70 laparoscopic nephro-ureterectomies (LNU) and 70 Mean warm ischemia time was 30 min (7-53 min) in the LPN open nephro-ureterectomies (ONU) for transitional cell and 28 min (6-50) in the OPN group. After 5 years from carcinoma of the upper urinary tract (TCC) were performed. operation, the biochemical markers of glomerular filtration The open procedure was reserved for patients with previous were completely normalized, demonstrating the absence of abdominal surgery or with severe cardiac and/or pulmonary renal injury. The definitive pathological results showed an problems. Demographic data, perioperative and postoperative incidence of 68% for renal clear-cell tumour, 13% for variables, tumour staging and histological grading and rates chromophobe tumour, 17% for angiomyolipoma and 2% for of metastasis were recorded and compared. benign complex cyst. The overall and cancer-specific survival Results: For LNU and ONU, respectively, mean operative rates at 5 years were 88% and 100%, respectively, in the LPN times were 240 min and 190 min; mean estimated blood loss group and 86% and 98% in the OPN group. was 70 ml in LNU and 120 ml in ONU. The definitive Conclusion: Laparoscopic partial nephrectomy, if pathology showed a high incidence of tumour stage pT2 G2 in performed by a skilled laparoscopist in expert centres, can both LNU and ONU groups. The median follow-up period was achieve oncological and functional outcomes that present no 60 months. In the LNU group, the 5-year disease-free survival relevant differences in comparison with the open procedure. was 75%: 100% for pTa, 88% for pT1, 78% for pT2, and 35% for pT3 (p<0.0001). In the ONU group, the 5-year disease-free survival was 73% (LNU-ONU; p=0.037): 100% for pTa, 89% 3 for pT1, 75% for pT2 and 31% for pT3 (p<0.0001). THE EXTENDED 14-CORE PROSTATE BIOPSY Conclusion: The results of our long-term controlled study SCHEME INCLUDING MIDLINE PERIPHERAL support the use of LNU as an effective alternative to an open SAMPLING IS MANDATORY IN PATIENTS WITH procedure in the therapy of upper urinary tract urothelial LOW PSA DENSITY cancer. Luigi Cormio, Fabrizio Lorusso, Oscar Selvaggio, Antonia Perrone, Giuseppe Di Fino, Mario De Siati, Pasquale 2 Annese, Francesca Sanguedolce, Pantaleo Bufo and LAPAROSCOPIC VERSUS OPEN PARTIAL Giuseppe Carrieri NEPHRECTOMY: ONCOLOGICAL AND FUNCTIONAL OUTCOMES OF A 5-YEAR Ospedali Riuniti di Foggia, Italy PROSPECTIVE STUDY IN 250 PATIENTS Aim: There is no general agreement on the ideal scheme for Francesco Greco, Sigrid Wagner, Raschid M Hoda, Felix transrectal prostate biopsy (TPB) and whether the scheme Kawan, Antonino Inferrera, Antonio Lupo and Paolo should be adjusted to patient clinical parameters. This study Fornara aimed to evaluate the diagnostic yield of an extended 14-core TPB scheme in detecting prostate cancer (PCa) and to Department of Urology and Kidney Transplantation, Martin identify those patients who would benefit most from such a Luther University, Halle/Saale, Germany scheme. 1377 ANTICANCER RESEARCH 30: 1375-1544 (2010) Patients and Methods: Between December 2005 and cores increases TPB diagnostic yield. The present study September 2009, 922 consecutive men underwent an aimed to determine whether duplication of lateral cores extended 14-core TPB because of serum PSA>4 ng/ml and/or sampling by another operator may improve the diagnostic abnormal digital rectal examination. The 14-core scheme yield of TPB. included sextant biopsies, 2 biopsies (one basal and one Patients and Methods: Between January 2008 and apical) in each lateral peripheral zone and 2 biopsies (one September 2009, 143 men scheduled by a single urologist for basal and one apical) in each midline peripheral zone. Each TPB because of serum PSA >4 ng/ml and/or abnormal digital core was numbered and analysed separately to determine the rectal examination underwent an extended 18-core biopsy overall detection rate of 6-, 10-, and 14-core biopsy schemes, scheme including our standard 14-core scheme (sextant as well as the detection rate according to serum PSA and biopsies + 2 biopsies, one basal and one apical, in each lateral prostate volume. Complications occurring up to 20 days after peripheral zone, + 2 biopsies, one basal and one apical, in the biopsy were also recorded. each midline peripheral zone) followed by duplication of Results: All procedures were carried out under local lateral peripheral zone sampling by another urologist. Each anaesthesia. PCa detection rate of 6-, 10-, and 14-core core was numbered and analysed separately to determine the schemes was 30.9% (285/922), 35.5% (328/922), and 37.2% overall detection rate of the 14- and 18-core biopsy schemes. (343/922), respectively, with an increase in diagnostic yield Complications occurring up to 20 days after the biopsy were of 14- vs. 6- and 10-core schemes of 10% and 4,5%, also recorded. respectively. When stratifying for clinical parameters, the Results: All procedures were carried out under local increase in diagnostic yield of the 14- vs. the 10-core scheme anaesthesia. While the addition of midline peripheral zone was greater in patients with low PSA levels (18.1%, 7.4%, sampling was found to be associated with a 4.9% increase in and 0% for serum PSA levels <4 ng/ml, 4 to 10 ng/ml, and diagnostic yield (44.7% vs. 42.6% for the 14- and the 10- >10 ng/ml, respectively), with large prostate volumes (6.7%, core scheme, respectively), duplication of lateral peripheral 4.1% and 3% for prostate volume >55 cc, 35 to 55 cc, and zone sampling did not change diagnostic yield at all. There <35 cc, respectively), and low PSA density (11% and 0.8% were no complications requiring hospitalization. for PSA density <0.15 and ≥0.15, respectively). There was no Conclusion: The present study shows that while the major complication requiring hospitalization. addition of midline peripheral sampling (the 14- vs. the 10- Conclusion: The present study confirms that the 10-core core scheme) increases the diagnostic yield of TPB by almost biopsy scheme provides better diagnostic yield than the 5%, the duplication of lateral peripheral sampling (the 18- vs. sextant scheme and should replace it as the standard protocol the 14- core scheme) even by a second operator does not for TPB. The extended 14-core scheme including midline increase the detection rate at all. peripheral sampling provides an overall increase in diagnostic yield of 4.5%; however, after stratifying for the evaluated clinical parameters (serum PSA, prostate volume and PSA 6 density) it becomes clear that it should be considered only in INTEGRATED STAGING SYSTEMS FOR patients with a serum PSA up to 10 ng/ml, and that it is most CONVENTIONAL RENAL CELL CARCINOMA: beneficial in patients with a low PSA density. A COMPARISON OF TWO PROGNOSTIC MODELS Martella Oreste 4 DUPLICATION OF LATERAL PERIPHERAL Division of Urology, Giuseppe Mazzini Hospital, Teramo, SAMPLING DOES NOT IMPROVE THE DETECTION Italy; Department of Health Sciences, L’Aquila University RATE OF THE EXTENDED 14-CORE TRANSRECTAL Medical School, L'Aquila, Italy PROSTATE BIOPSY SCHEME Objective: The objective of the current study was to compare, Luigi Cormio, Fabrizio Lorusso, Oscar Selvaggio, Antonia in a single centre experience, the discriminating accuracy of Perrone, Giuseppe Di Fino, Mario De Siati, Francesca two prognostic models to predict the outcome of patients Sanguedolce, Pantaleo Bufo and Giuseppe Carrieri surgically treated for conventional renal cell carcinoma (RCC).
Load more

Recommended publications
  • Urologic Malignancies
    Scope • Anatomy •Urologic Malignancies • Trauma • Emergencies • Infections • Lower Urinary Tract Obstruction • Upper Urinary Tract Obstruction • Pediatric Urology • Key Points Emmanuel L. Barcenas Urologist/Urologic Surgeon Urology Specialty Group and Associates • Doctor of Medicine, SWU • Diplomate, Philippine Board of Surgery and the Philippine Board of Urology • Fellow, Philippine Urological Association • Fellow, Philippine College of Surgeons • Member, Philippine Endourological Society • Member, Phillippine Society of Urooncologists Urologic Malignancies Urologic Malignancies •Bladder Cancer •Testicular Cancer •Kidney Cancer •Prostate Cancer Urothelial Tumors of the UB •Transitional cell epithelium lines the urinary tract from the renal pelvis, ureter, urinary bladder, and the proximal two-thirds of the urethra •Tobacco use is the most frequent risk factor (50% in men and 40% in women), followed by occupational exposure to various carcinogenic materials such as automobile exhaust or industrial solvents. Detection of Urothelial Cancer •Painless gross hematuria occurs in 85% of patients & requires a complete evaluation that includes cystoscopy, urine cytology, CT scan, & a PSA. •Recurrent or significant hematuria (>3 RBC’s/HPF on 3 urinalysis, a single urinalysis with >100 RBCs, or gross Hematuria) is associated with significant renal or urologic lesion in 9.1% Detection of Urothelial Cancer • Patients with microscopic hematuria require a full evaluation, but low-risk patients do not require repeat evaluations. • High-risk individuals primarily are those with a smoking history & should be evaluated every 6 months. • The level of suspicion for urogenital neoplasms in patients with isolated painless hematuria and nondysmorphic RBCs increases with age. • White light cystoscopy with random bladder biopsies is the gold standard for tumor detection History & Staging •Low-grade papillary lesions are likely to recur in up to 60% of patients but invade in less than 10% of cases.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,682,960 B2 Labrie Et Al
    USOO968296OB2 (12) United States Patent (10) Patent No.: US 9,682,960 B2 Labrie et al. (45) Date of Patent: Jun. 20, 2017 (54) NON-STEROIDAL ANTANDROGENS AND (56) References Cited SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH APYRIDYL MOETY U.S. PATENT DOCUMENTS 3,742.951 7, 1973 Zaffaroni (71) Applicants: Fernand Labrie, Quebec (CA); 3,797.494 3, 1974 Zaffaroni Shankar Mohan Singh, Quebec (CA); 4,568,343 2, 1986 Leeper et al. Richard Labrecque, St-Nicolas (CA); 5,064,654 11, 1991 Berner et al. 5,071,644 12, 1991 Viegas et al. Liviu Constantin Ciobanu, Quebec 5,071,657 12, 1991 Oloff et al. (CA) 5,411,981 5, 1995 Gaillard-Kelly et al. 5,556,983 9, 1996 Claussner et al. (72) Inventors: Fernand Labrie, Quebec (CA); 5,750,553 5, 1998 Claussner et al. 6,071,957 6/2000 Miller et al. Shankar Mohan Singh, Quebec (CA); 7/2000 Claussner et al. Richard Labrecque, St-Nicolas (CA); 6,087,509 Liviu Constantin Ciobanu, Quebec (Continued) (CA) FOREIGN PATENT DOCUMENTS (73) Assignee: ENDORECHERCHE, INC. (CA) CA 2 677 295 9, 2008 CA 2 773 591 3, 2011 EP 0 002892 A1 7/1979 (*) Notice: Subject to any disclaimer, the term of this EP O 100 172 A1 2, 1984 patent is extended or adjusted under 35 EP O 279 982 A1 8, 1988 U.S.C. 154(b) by 0 days. EP O 494 819 A1 7, 1992 EP O 578516 A1 1, 1994 Appl. No.: 14/567,970 EP O 580 459 A1 1, 1994 (21) FR 2 671 348 A1 7, 1992 Filed: Dec.
    [Show full text]
  • Guidelines on Testicular Cancer
    GUIDELINES ON TESTICULAR CANCER (Limited text update March 2015) P. Albers (Chair), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, K. Fizazi, A. Horwich, M.P. Laguna, N. Nicolai, J. Oldenburg Eur Urol 2011 Aug;60(2):304-19 Introduction Compared with other types of cancer, testicular cancer is relatively rare accounting for approximately 1-1.5% of all cancers in men. Nowadays, testicular tumours show excellent cure rates, mainly due to early diagnosis and their extreme chemo- and radiosensitivity. Staging and Classification Staging For an accurate staging the following steps are necessary: Postorchiectomy half-life kinetics of serum tumour markers. The persistence of elevated serum tumour markers after orchiectomy may indicate the presence of disease, while their normalisation does not necessarily mean absence of tumour. Tumour markers should be assessed until they are normal, as long as they follow their half-life kinetics and no metastases are revealed. A chest CT scan should be routinely performed in patients diagnosed with non-seminomatous germ cell tumours (NSGCT), because in up to 10% of cases, small subpleural nodes may be present that are not visible radiologically. 110 Testicular Cancer Recommended tests for staging at diagnosis Test Recommendation GR Serum tumour markers Alpha-fetoprotein A hCG LDH Abdominopelvic CT All patients A Chest CT All patients A Testis ultrasound (bilateral) All patients A Bone scan or MRI columna In case of symptoms Brain scan (CT/MRI) In case of symptoms and patients with meta- static disease with mul- tiple lung metastases and/or high beta-hCG values. Further investigations Fertility investigations: B Total testosterone LH FSH Semen analysis Sperm banking should be offered.
    [Show full text]
  • Paratesticular Metastasis of High Grade Prostate Cancer Clinically
    CASE REPORT Urooncology Doi: 10.4274/jus.481 Journal of Urological Surgery, 2017;4:26-28 Paratesticular Metastasis of High Grade Prostate Cancer Clinically Mimicking Hemato/Pyo-hydrocele Paratestiküler Metastazla Presente Olan Yüksek Dereceli Prostat Adenokarsinomu Hikmet Köseoğlu1, Şemsi Altaner2 1Başkent University Faculty of Medicine, Department of Urology, İstanbul, Turkiye 2Başkent University Faculty of Medicine, Department of Pathology, İstanbul, Turkiye Abstract Secondary metastatic lesions of the testicles are very rare and they originate mainly from prostate adenocarcinoma. They are generally diagnosed incidentally, however, they very rarely manifest as a palpable testicular mass. In this paper, we present, a case of paratesticular metastasis from high- grade prostate cancer clinically mimicking pyo-/hemato-/hydrocele. A 75-year-old man, who had been followed up elsewhere for a huge hydrocele based on scrotal Doppler ultrasonography and scrotal magnetic resonance imaging reporting no suspicion for malignancy, but a pyo-/hemato-/ hydrocele was determined to have testicular metastasis originating from prostate adenocarcinoma. Keywords: Hydrocele, testis, neoplasm metastasis, prostate, adenocarcinoma Öz Testisin metastatik lezyonları oldukça nadirdir ve çoğunlukla prostat kanserinden köken almaktadırlar. Genellikle rastlantısal olarak tanı alırlar; ancak çok nadir testiste palpe edilebilen kitle ile belirti verirler. Bu olgu bildirisinde klinik olarak pyo-/hemato-/hidrosel olarak izlenen olguda yüksek dereceli prostat kanseri metastazı
    [Show full text]
  • (A) Administrative Information Advanced Urooncology Course URL
    Course SPECIFICATION Faculty of Medicine- Mansoura University Urology (A) Administrative information (1) Programme offering the course: URL 623 (2) Department offering the programme: Urology Department (3) Department responsible for teaching the Urology Department course: (4) Part of the programme: Prof. Dr. Ahmed Mosbah (5) Date of approval by the Department`s council May, 2016 (6) Date of last approval of programme 9/8/2016 specification by Faculty council (7) Course title: Advanced urooncology course (8) Course code: URL 623 AUO (9) Credit hours 1 hour (10) Total teaching hours: 14 theoretical hours 1 (B) Professional information (1) Programme Aims: The general aim of the course is to provide postgraduate students with the knowledge, skills and some attitudes necessary to make an essential urologic framework of the urologist including awareness of the common urologic emergencies. 1- Enlist the etiology, pathology, diagnosis and treatment of urologic tumours. 2- Describe emergencies related to urologic oncology and how to deal with it. 3- Define the steps of performing radical nephrectomy, radical cystectomy, radical prostatectomy, high inguinal orchiectomy and penectomy. 4- Practice urologic oncology in the outpatient clinic under supervision by the faculty members. 5- Study how to evaluate the urologic oncology patient. 6- Design a research proposal and how to implement and publish it. 7- Describe different modalities of treatment of urologic tumours other than surgery. (2) Intended Learning Outcomes (ILOs): Intended learning outcomes (ILOs); Are four main categories: knowledge & understanding to be gained, intellectual qualities, professional/practical and transferable skills. On successful completion of the programme, the candidate will be able to: A- Knowledge and Understanding K1 Biological behavior of all urologic tumours.
    [Show full text]
  • WO 2018/144603 Al 09 August 2018 (09.08.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/144603 Al 09 August 2018 (09.08.2018) W !P O PCT (51) International Patent Classification: A61K 38/09 (2006 .01) A61P 35/00 (2006.0 1) (21) International Application Number: PCT/US20 18/0 16241 (22) International Filing Date: 31 January 2018 (3 1.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/452,788 31 January 2017 (3 1.01.2017) US (71) Applicant: VERU INC. [US/US]; 4400 Biscayne Blvd., #888, Miami, Florida 33 137 (US). (72) Inventors: RAVI, Kacker; 39 Paul Revere Road, Lexing ton, Massachusetts 02421 (US). MITCHELL S., Stein- er; 2600 Forest Hill Road, Germantown, Tennessee 38139 (US). (74) Agent: COHEN, Mark S. et al; PEARL COHEN ZEDEK LATZER BARATZ LLP, 1500 Broadway, 12th Floor, New York, New York 10036 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Spectrum Pharmaceuticals Initiates US Clinical
    Spectrum Pharmaceuticals Initiates U.S. Clinical Trial of Ozarelix (SPI-153) in Patients with Hormone-Dependent Prostate Cancer - Ozalerix is currently in two multicenter trials underway in Europe - one in benign prostate hypertrophy (BPH) and another in hormone dependent prostate cancer - Spectrum now has five drugs in multiple clinical trials, including one in phase III IRVINE, Calif., July 25 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced the launch of a phase I/II trial in the United States to explore the safe and efficacious dose range of ozarelix (formerly SPI-153) as a treatment for patients with hormone- dependent prostate cancer. "We are pleased to advance the development of ozarelix in the United States with the start of this clinical study," stated Rajesh Shrotriya, M.D., Chairman of the Board, Chief Executive Officer and President of Spectrum Pharmaceuticals, Inc. "This study will provide us additional valuable information regarding the optimum dose range for testosterone suppression, an important outcome measure in the management of hormone-dependent prostate cancer." About Prostate Cancer Prostate cancer is the second leading cause of cancer deaths in men and occurs when a malignant tumor forms in the tissue of the prostate. According to figures released by the American Cancer Society, approximately 232,090 new cases and 30,350 deaths will occur in the U.S. during 2005. The initial treatment of prostate cancer included surgery along with radiation therapy and hormonal therapy. About Ozarelix Ozarelix is a fourth generation LHRH (Luteinizing Hormone Releasing Hormone), also known as GnRH (Gonadotropin Releasing Hormone), antagonist. LHRH antagonists have the potential to treat hormone-dependent cancers as well as benign proliferative disorders such as benign prostatic hypertrophy and endometriosis.
    [Show full text]
  • Castrating Pedophiles Convicted of Sex Offenses Against Children: New Treatment Or Old Punishment
    SMU Law Review Volume 51 Issue 2 Article 4 1998 Castrating Pedophiles Convicted of Sex Offenses against Children: New Treatment or Old Punishment William Winslade T. Howard Stone Michele Smith-Bell Denise M. Webb Follow this and additional works at: https://scholar.smu.edu/smulr Recommended Citation William Winslade et al., Castrating Pedophiles Convicted of Sex Offenses against Children: New Treatment or Old Punishment, 51 SMU L. REV. 349 (1998) https://scholar.smu.edu/smulr/vol51/iss2/4 This Article is brought to you for free and open access by the Law Journals at SMU Scholar. It has been accepted for inclusion in SMU Law Review by an authorized administrator of SMU Scholar. For more information, please visit http://digitalrepository.smu.edu. CASTRATING PEDOPHILES CONVICTED OF SEX OFFENSES AGAINST CHILDREN: NEW TREATMENT OR OLD PUNISHMENT? William Winslade* T. Howard Stone** Michele Smith-Bell*** Denise M. Webb**** TABLE OF CONTENTS I. INTRODUCTION ........................................ 351 II. PEDOPHILIA AND ITS TREATMENT ................. 354 A. THE NATURE OF PEDOPHILIA ......................... 355 1. Definition of Pedophilia ........................... 355 2. Sex Offenses and Sex Offenders ................... 357 a. Incidence of Sex Offenses ..................... 357 b. Characteristics of and Distinctions Among Sex O ffenders ..................................... 360 B. ETIOLOGY AND TREATMENT .......................... 364 1. Etiology and Course of Pedophilia................. 364 2. Treatment ......................................... 365 a. Biological of Pharmacological Treatment ...... 366 * Program Director, Program on Legal & Ethical Issues in Correctional Health, In- stitute for the Medical Humanities, James Wade Rockwell Professor of Philosophy of Medicine, Professor of Preventive Medicine & Community Health, and Professor of Psy- chiatry & Behavioral Sciences, University of Texas Medical Branch, Galveston, Texas; Dis- tinguished Visiting Professor of Law, University of Houston Health Law & Policy Institute.
    [Show full text]
  • View Annual Report
    Spectrum Pharmaceuticals, Inc. CANCER TAKES THE LIVES OF OVER SEVEN MILLION PEOPLE WORLDWIDE EACH YEAR www.spectrumpharm.com 157 Technology Drive, Irvine, California 92618 Telephone 949.788.6700 2005 Annual Report spECTRUM PHARMACEUTicALS, INC. SPECTRUM O U R T E A M PHARMACEUTicALS BOARD OF DIRECTORS MANAGEMENT TEAM OUTSIDE COUNSEL Rajesh C. Shrotriya, M.D. Rajesh C. Shrotriya, M.D. Latham & Watkins LLP Chairman of the Board, Chief Executive Officer Chairman, Chief Executive Officer & President Costa Mesa, California is COMMITTED TO & President, Spectrum Pharmaceuticals, Inc. Luigi Lenaz, M.D. I NDEPENDENT A UDITORS Richard D. Fulmer, M.B.A. Chief Scientific Officer Kelly & Company Former Vice President, Licensing and Development, Costa Mesa, California IMPROVING THE and Vice President of Marketing, Pfizer Inc. Shyam K. Kumaria, CPA, MBA Vice President, Finance T R A N S F E R A GENT Stuart M. Krassner, Sc.D., Ph.D. U.S. Stock Transfer Corporation LIVES OF PEOPLE Professor Emeritus of Developmental and Russell L. Skibsted Glendale, California Cell Biology at the School of Biological Sciences Senior Vice President, Chief Business Officer University of California at Irvine SEC F O R M 1 0 - K Ashok Y. Gore, Ph.D. Please see the enclosed Annual Report on Form WHO ARE FIGHTING Anthony E. Maida, III, M.A., M.B.A. Senior Vice President, Pharmaceutical 10-K filed with the Securities and Exchange Chairman, BioConsul Drug Development Operations & Regulatory Compliance Commission for a more detailed description Corporation and DendriTherapeutics, Inc. of the Company’s business, financial and other Consultant to various Venture Capital, William N.
    [Show full text]
  • Spectrum Announces Completion of Patient Enrollment in Ozarelix Phase II Trial in Patients with Benign Prostatic Hypertrophy
    Spectrum Announces Completion of Patient Enrollment in Ozarelix Phase II Trial in Patients With Benign Prostatic Hypertrophy * Enrollment was completed ahead of schedule by more than four months * This is a multicenter, placebo controlled, randomized study in 144 patients with BPH IRVINE, Calif., Nov 21, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that the Company has achieved complete enrollment for a phase II trial of ozarelix in Benign Prostatic Hypertrophy (BPH), more that four months ahead of schedule. The multi-center clinical trial is designed to evaluate both objective parameters, such as improvement in urine flow and shrinkage of the prostate volume, as well as various symptoms of BPH over a period of several months. The trial is conducted in Europe with the collaboration of AEterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ), "We are pleased to report that this multicenter, placebo controlled, randomized, phase II trial that was started only in April this year, has already achieved its goal of enrolling 144 patients, ahead of our projections by more than four months," stated Rajesh C. Shrotriya, M.D., Chairman, Chief Executive Officer and President. "Non-cancerous, enlargement of the prostate (BPH) adversely affects the quality of life, leading to increased frequency of urination and difficulty in passing urine. Because ozarelix is expected to have dual effects: (1), by directly shrinking the prostate and (2), through controlled reduction in the amount of testosterone (testosterone fuels the prostate gland), our expectation is that a single injection of ozarelix, repeated every few months, may be able to reduce the size of the prostate as well as accompanying symptoms." About Benign Prostatic Hypertrophy Benign prostatic hypertrophy is a non-cancerous enlargement of the prostate frequently occurring in men over the age of 50.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0190692 A1 VAN GROENINGHEN (43) Pub
    US 20100190692A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0190692 A1 VAN GROENINGHEN (43) Pub. Date: Jul. 29, 2010 (54) METHODS FOR REDUCING Publication Classification GNRH-POSITIVE TUMIORCELL (51) Int. Cl. PROLIFERATION A638/09 (2006.01) (76) Inventor: JOHANNES C. VAN A638/22 (2006.01) GROENINGHEN, Dortmund (DE) A 6LX 3/59 (2006.01) s A63L/704 (2006.01) Correspondence Address: Age, 30.8; } GRUND INTELLECTUAL PROPERTY GROUP NKOLAISTRASSE 15 (52) U.S. Cl. .............. 514/8: 514/15; 514/259.5; 514/34; (57) ABSTRACT (21) Appl. No.: 12/701,284 A method for recognizing and evaluating the presence and (22) Filed: Feb. 5, 2010 function of GnRH receptors on tumor cells originating in the brain and/or nervous system and/or the meninges and/or reac Related U.S. Application Data tive neuroglia cells and/or primitive neuroectodermal tumor cells and/or on Kaposi sarcoma is provided. Furthermore a (63) Continuation-in-part of application No. 10/327,621, method for reducing degenerate GnRH-positive tumor cells filed on Dec. 20, 2002, now Pat. No. 7,695,722, which and/or for decreasing cellular replication of the above GnRH is a continuation-in-part of application No. 09/446, positive tumor cells comprising administering to a cell or to a 996, filed on Dec. 30, 1999, now abandoned, filed as Subject a replication decreasing amount of a GnRH agonist application No. PCT/DE98/01902 on Jul. 3, 1998. and/or GnRH antagonist and/or an erythropoietin agonist, and/or a thrombopoietin agonist, and/or a endothelin antago (30) Foreign Application Priority Data nist and/or a gonadotropin inhibiting hormone agonist is also provided.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,853,266 B2 Dalton Et Al
    USOO8853266B2 (12) United States Patent (10) Patent No.: US 8,853,266 B2 Dalton et al. (45) Date of Patent: *Oct. 7, 2014 (54) SELECTIVE ANDROGEN RECEPTOR 3,875,229 A 4, 1975 Gold MODULATORS FOR TREATING DABETES 4,036.979 A 7, 1977 Asato 4,139,638 A 2f1979 Neri et al. 4,191,775 A 3, 1980 Glen (75) Inventors: James T. Dalton, Upper Arlington, OH 4,239,776 A 12/1980 Glen et al. (US): Duane D. Miller, Germantown, 4,282,218 A 8, 1981 Glen et al. TN (US) 4,386,080 A 5/1983 Crossley et al. 4411,890 A 10/1983 Momany et al. (73) Assignee: University of Tennessee Research 4,465,507 A 8/1984 Konno et al. F dati Kn ille, TN (US) 4,636,505 A 1/1987 Tucker Oundation, Knoxv1lle, 4,880,839 A 1 1/1989 Tucker 4,977,288 A 12/1990 Kassis et al. (*) Notice: Subject to any disclaimer, the term of this 5,162,504 A 11/1992 Horoszewicz patent is extended or adjusted under 35 5,179,080 A 1/1993 Rothkopfet al. U.S.C. 154(b) by 992 days. 5,441,868 A 8, 1995 Lin et al. 5,547.933 A 8, 1996 Lin et al. This patent is Subject to a terminal dis- 5,609,849 A 3/1997 Kung claimer. 5,612,359 A 3/1997 Murugesan et al. 5,618,698 A 4/1997 Lin et al. 5,621,080 A 4/1997 Lin et al. (21) Appl. No.: 11/785,064 5,656,651 A 8/1997 Sovak et al.
    [Show full text]